【摘要】 目的探讨造血细胞磷酸酶(SHP1)基因和天冬酰胺特异酶切的半胱氨酸蛋白酶(Caspase1、3)基因表达与白血病患者的化疗效果的关系。方法用RTPCR方法检测白血病患者骨髓单个核细胞中SHP1和Caspase1、3的mRNA表达。结果急性白血病(AL)患者SHP1和Caspase1、3表达率分别为33.3%、80.0%、100.0%;慢性髓细胞白血病(CML)患者SHP1表达率在急变期、慢性期分别为0.0%、37.5%。SHP1和Caspase1、3基因阳性患者的首次完全缓解(CR)率分别为85.0%、64.3%、55.8%,明显高于阴性患者(分别为15.6%、20.0%),差异均有统计学意义(P<0.05);Caspase1、3与SHP1表达呈正相关。结论SHP1可能是一个潜在的抑癌基因,它可能是通过激活下游的凋亡基因Caspase1、3发挥作用;Caspase1、3与SHP1基因表达呈正相关且与病人的CR率有关,表明它们均参与了白血病的转归,可同时作为判断白血病患者的疗效和预后指标。更多还原

【Abstract】 Objective To evaluate the relationship between the expression of hematopoietic cell phosphatase (SHP-1) gene or cysteinyl aspartate-specific proteinases (Caspase-1,3) gene and the effect of chemotherapy in leukemia patients. Methods The expression of SHP-1 and Caspase-1,3 gene was measured in leukemia patients with reverse transcriptase-polymerase chain reaction. Results The positive rate of SHP-1 and Caspase-1,3 gene in acute leukemia was 33.3%, 80.0% and 100.0%. The positive rate of SHP-1 in chronic myeloid leukemia (CML) -blastic phase and CML-chronic phase was 0.0%, 37.5%. The first complete remission(CR)rate of SHP-1 and Caspase-1,3 positive group was 85.0%,64.3% and 55.8%,which were higher than that of SHP-1 and Caspase-1,3 negative group (P<0.05). There was a positive correlation between SHP-1 and Caspase-1,3. Conclusions SHP-1 gene is potentially an anti-oncogene and may play a role through activation of Caspase-1,3 gene. The expression of SHP-1 and Caspase-1,3 is associated with remission rate and it is shown that they participate in the prognosis of leukemia . They could be used as indices for evaluating therapeutic efficacy and judging prognosis in leukemia patients.更多还原